Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $54.1 million.

  • Fulcrum Therapeutics' Shares Outstanding (Weighted Average) fell 13.32% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year decrease of 13.32%. This contributed to the annual value of $53.9 million for FY2024, which is 12.75% down from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Shares Outstanding (Weighted Average) of $54.1 million as of Q3 2025, which was up 0.21% from $54.0 million recorded in Q2 2025.
  • Fulcrum Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $62.4 million during Q3 2024, with a 5-year trough of $32.7 million in Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $61.8 million (2023), whereas its average is $59.1 million.
  • Per our database at Business Quant, Fulcrum Therapeutics' Shares Outstanding (Weighted Average) skyrocketed by 51.98% in 2023 and then dropped by 13.32% in 2025.
  • Over the past 5 years, Fulcrum Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $40.5 million in 2021, then climbed by 28.37% to $52.1 million in 2022, then rose by 18.77% to $61.8 million in 2023, then declined by 12.75% to $53.9 million in 2024, then decreased by 13.32% to $54.1 million in 2025.
  • Its last three reported values are $54.1 million in Q3 2025, $54.0 million for Q2 2025, and $54.0 million during Q1 2025.